The Syndrome That Chronic Kidney Disease(CKD)3of Kidney Yin Deficiency Research Based On The Metabonomics

Objective:Using super high performance liquid chromatography and series level4pole flight time mass spectrometry (UPLC-Q-TOF/MS) metabolomics research technology, the healthy crowd, chronic kidney disease in patients withstage3liver and kidney Yin deficiency urine to the full spectrum analysis, search for chronic kidney disease (CKD)3of kidney Yin deficiency syndrome types related biomarkers of (group)ï¼› Attempts to explore the metabonomics level3of chronic kidney disease (CKD) kidney Yin deficiencyof traditional Chinese medicine "card" of the material base.Method: Choose Heilongjiang academy of traditional Chinese medicine clinic chronic kidney disease patients withstage3in June to December of2011. and accordingto the traditional Chinese medicine research guiding principle, liver and kidney Yin deficiency syndrome differentiationbelongs to the observation group of15cases, and the other in our hospital medical examination randomly selected15cases of healthy controls. Enrol your biometrics subjects since morning urine, OPLS-DA analysis, through the above analysis for metabolic fingerprint, the chart of pretreatmentand integral, the integral value multivariate analysis, according to each sample of principal component score mapping,can be the difference between discriminant group; And according to the contribution of each ion VIP values greater than4ion sure chronic kidney disease (CKD)3of liver and kidney Yin deficiency of potential biomakers; Application Q-TOF or TOF sure compounds accurate quality, throughthe relevant database retrieval, ultimately through chemical information retrieval, chromatographic retention behavior and MS/MS data to speculate that the markers compound structure, preliminary test this path metabolism product structure identification validity; Ultimately for OPLS-DA and VIP values of potential biomakers for structure analysis, massspectrometry of peak level1HNMR extraction, get motherion mass spectrum information (Rt_m/z), reduction of chromatographic peak of TIC figure, at multiple collision canunder the level2mass spectrometry scanning with satisfactory secondary mass spectrum information, determine the corresponding markers son ion pieces, further combining literature information and mass spectrometry apportionment structure confirmation, application massfragment software structure, the validity of discrimination.Results: Chronic kidney disease (3)3of liver and kidney Yin deficiency group and control group in mass spectrometry outline the BPI map shows: the control group andchronic kidney disease (CKD)3of liver and kidney Yindeficiency group can obviously to distinguish, between thetwo groups there are significant differences.(4) accordingto chronic kidney disease (CKD)3of liver and kidney Yin deficiency group and the normal control group of S-plotand VIP value, the masslynx software system nested massfragment software analysis of the significant difference ofcompounds for Phenylacetic acid,N-Heptanoylglycine,L-beta-aspartyl-L-alanine, Vanilpyruvic acid, Pantothenic acid, Butyrylcarnitine,Valerylcarnitine,Alpha-Aspartyl-lysine,N-Acetylcystathionine,4-Hydroxyphenylacetylglutamine,N-Acetyl-a-neuraminic acid,2-trans,4-cis-Decadienoylcarnitine,9-Decenoylcarnitine, Farnesylcysteine, beta-monoacylglycerol, S-(Hydroxymethyl)glutathione, Pantetheine4'-phosphate. Conclusion: Chronic kidney disease in patients with stage3liver and kidney Yin deficiency urine metabolism and the general population spectrum compared with significant differences, can will chronic kidney disease (CKD)3ofkidney Yin deficiency syndrome patients and healthy peopleto distinguish; Chronic kidney disease (CKD)3of liver and kidney Yin deficiency compared with normal people there has been a marked change, can pass the metabonomicsmethod for to seek a chronic kidney disease (CKD)3of liver and kidney Yin deficiency potential biological markers.